NCT07091019View on ClinicalTrials.gov

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

Not yet recruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

May 15, 2033

Study Completion Date

May 15, 2033

Conditions

Chronic Myelogenous Leukemia - Chronic Phase

Interventions

OTHER

TKIs

There is no treatment allocation for NIS trials. Patients administered TKI (asciminib, bosutinib, dasatinib, imatinib, nilotinib) by prescription will be enrolled.